Blinatumomab patent expiration?

When Does Blinatumomab Patent Expire?

Blinatumomab is a medication used to treat acute lymphoblastic leukemia (ALL) and B-cell precursor acute lymphoblastic leukemia. The drug is sold under the brand name Blincyto and is developed by Amgen.

According to DrugPatentWatch.com [1], the original patent for Blincyto (blinatumomab) expires in the United States on December 31, 2028.

How Will Patent Expiration Affect the Price of Blincyto?

Patent expiration can lead to increased competition in the market, which may result in lower prices for the medication. Generic or biosimilar versions of Blincyto could enter the market, allowing pharmaceutical companies other than Amgen to produce and sell the drug. This increased competition may drive prices down.

Why Are Companies Developing Biosimilars for Blincyto?

Companies like Biocon and Mylan have been developing biosimilars for Blincyto, which allows them to create a cheaper alternative without infringing on the original patent. Biosimilars must demonstrate a high degree of similarity to the original medication in terms of efficacy and safety, which can be an expensive and complex process.

Will Biosimilars Be Allowed to Enter the Market Before the Patent Expires?

Under current regulations, biosimilars are allowed to enter the market 12 years after the original product was approved by the FDA. In the case of Blincyto, this means that biosimilars could potentially enter the market in 2030, although this is subject to change based on various factors.

Sources:

[1] DrugPatentWatch.com: Blincyto (blinatumomab) patent expiry [https://www.drugpatentwatch.com/drug/Blincyto]

(Note: The list of sources is limited to one due to the lack of specific request for multiple sources)